Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future

Abstract

Get full access to this article

View all access options for this article.

References

Bogenschutz

Forcehimes

Pommy

. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29: 289–299.

Carhart-Harris

Erritzoe

Williams

. (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–2143.

Carhart-Harris

Leech

Williams

. (2012b) Implications for psychedelic-assisted psychotherapy: a functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200: 238–244.

Carhart-Harris

Muthukumuraswarmy

Moran

. (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33: 15171–15183.

Carhart-Harris

Bolstridge

Rucker

. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.

Griffiths

Johnson

Carducci

. (2016) Psilocybin produces substantial and sustained decrease in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30: 1181-1197.

Griffiths

Johnson

Richards

. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218: 649–665.

Griffiths

Richards

Johnson

. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.

Griffiths

Richards

McCann

. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268–283; discussion 284–292.

10.

Grob

Danforth

Chopra

. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.

11.

Johnson

Garcia-Romeu

Cosimano

. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28: 983–992.

12.

Kometer

Schmidt

Bachmann

. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72: 898–906.

13.

Krebs

Johansen

P-Ø

(2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacology 26: 994–1002.

14.

Moreno

Wiegand

Taitano

Delgado

(2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67: 1735–1740.

15.

Pokorny

Preller

Kraehenmann

. (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26: 756–766.

16.

Ross

Bossis

Guss

. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30: 1165-1180.

17.

Vollenweider

Vollenweider-Scherpenhuyzen

Bäbler

. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897–3902.